Day: November 10, 2025

HOUSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) — Occidental (NYSE: OXY) today announced its third quarter 2025 financial results. The earnings release and accompanying financial schedules can be accessed via the Investor Relations section of the company’s website at oxy.com. The earnings release is also available on the U.S. Securities and Exchange Commission’s website at sec.gov. The company will hold a conference call to discuss the results on Tuesday, November 11, 2025, at 1 p.m. Eastern/12 p.m. Central. The conference call may be accessed by calling 1-866-871-6512 (international callers dial 1-412-317-5417) or via webcast at oxy.com/investors. Participants may pre-register for the conference call at https://dpregister.com/sreg/10202923/ffe6d67319. A recording of the webcast will be posted on the Investor Relations section of the company’s...

Revenue: $7.4 million, 41% YoY increaseNet Income: $0.6 millionTransaction Volumes up 43% YoYBitcoin Investment Treasury Holdings: 1,526 BTC1 PHOENIX, Nov. 10, 2025 (GLOBE NEWSWIRE) — Fold Holdings, Inc. (NASDAQ: FLD) (“Fold”, “we”, or “our”), the first publicly traded bitcoin financial services company, today announced financial results for the third quarter ended September 30, 2025. Financial HighlightsRevenue: $7.4 million; 41% YoY increase Net Income: $0.6 million Adjusted EBITDA2 (Loss): ($4.2) million Earnings Per Share: $0.01 per share Adjusted EBITDA (Loss) Per Share2: ($0.09) per share Bitcoin Investment Treasury Holdings1: 1,526 BTCKey Operating MetricsTotal Transaction Volume: $235 million; 43% YoY increase Total Active Accounts: 625,000+, added +7,500 new accounts in the quarter Total Verified Accounts: 82,000+,...

Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025 More than half of the patients required for the Phase 3 REGEN-006 (PROACT 1) accelerated approval analysis using estimated glomerular filtration rate (eGFR) slope have been enrolled; topline results anticipated in Q2 2027 Ended the third quarter with $272 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027WINSTON-SALEM, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the third quarter ended September 30, 2025, and...

LONG BEACH, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab”, “the Company”, “we,” “us,” or “our”), a global leader in launch services and space systems, today shared the financial results for fiscal third quarter ended September 30, 2025. Rocket Lab founder and CEO, Sir Peter Beck, said: “This past quarter we’ve once again delivered record revenue of $155m at record GAAP gross margin of 37%, and a new annual launch record is just days away. With progress across our major space systems programs, record backlog of contracts for our launch services business, and well-timed, strategic M&A in growth areas that are well-aligned with next-generation defense programs like Golden Dome and the Space Development Agency’s future constellations, our momentum is strong and we’re poised to deliver...

Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia set to launch in November Tonmya is the first new FDA-approved medicine for fibromyalgia in more than 15 years Cash and cash equivalents of $190.1 million reported as of September 30, 2025; current cash runway expected to fund operations into the first quarter of 2027 CHATHAM, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biotechnology company today announced financial results for the third quarter ended September 30, 2025, and provided an overview of recent operational highlights. “Following U.S. Food and Drug Administration (FDA) approval of Tonmya™, we are focused on execution of the U.S. launch later this month to bring the first...

Revenues of $108.4 million compared to $100.6 million in the prior year period Pretax income of $7.0 million compared to $6.9 million in the prior year period New contract purchases of $391.1 million in the quarterLAS VEGAS, NV, Nov. 10, 2025 (GLOBE NEWSWIRE) — Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced earnings of $4.9 million, or $0.20 per diluted share, for its third quarter ended September 30, 2025. This represents an increase compared to net income of $4.8 million, or $0.20 per diluted share, in the third quarter of 2024. Revenues for the third quarter of 2025 were $108.4 million, an increase of $7.8 million, or 7.8%, compared to $100.6 million for the third quarter of 2024. Total operating expenses for the third quarter of 2025 were $101.4 million compared to $93.7 million...

Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study Aligned with the U.S. Food and Drug Administration (FDA) on an analytical approach to establish comparability of a high-productivity, suspension-based PBFT02 manufacturing process On track to obtain regulatory feedback on FTD-GRN registrational trial design in 1H 2026 Cash runway into 1Q 2027 PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the third quarter ended September 30, 2025, and provided recent business highlights. “We are pleased to report that we have opened enrollment in our third FTD-GRN and first FTD-C9orf72 patient cohorts in our...

SEOUL, Korea, Nov. 10, 2025 (GLOBE NEWSWIRE) — DoubleDown Interactive Co., Ltd. (NASDAQ: DDI) (“DoubleDown” or the “Company”), a leading developer and publisher of digital games on mobile and web-based platforms, today announced unaudited financial results for the third quarter ended September 30, 2025. Beginning with the fourth quarter of 2024, the Company began reporting financial results in accordance with International Financial Reporting Standards (“IFRS”), which had previously been reported in accordance with U.S. Generally Accepted Accounting Principles (“US GAAP”). As such, the third quarter 2025 results, as well as the comparable 2024 results, reflect IFRS standards. Third Quarter 2025 vs. Third Quarter 2024 Summary:Revenue rose 15.5% to $95.8 million in the third quarter of 2025 compared to $83.0 million in the third...

Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital from Medtronic and Ligand, as well as $30 million from TerumoInitiated patient enrollments in the Virtue Trial evaluating Virtue® Sirolimus AngioInfusion™ Balloon (“Virtue SAB”) trial versus commercially available paclitaxel-coated balloonDemonstrated partnership-driven business model execution with expanded strategic collaboration with Medtronic and new right of first refusal agreement with TerumoNEW HOPE, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing...

Continued Investment in our Long-Term Strategic Plan NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — Vroom, Inc. (Nasdaq:VRM) today announced financial results for the third quarter ended September 30, 2025. HIGHLIGHTS OF THIRD QUARTER 2025$59.2 million consolidated total available liquidity(1) as of September 30, 2025, consisting of:$12.4 million cash and cash equivalents         $11.8 million of liquidity available to UACC under the warehouse credit facilities $35.0 million of available liquidity from delayed draw facility, further strengthening our liquidity position to execute our long-term strategy$(27.1) million net loss from continuing operations for the three months ended September 30, 2025 $(25.7) million adjusted net loss(2) for the three months ended September 30, 2025$(15.3) million unfavorable mark-to-market for...